Table 2.

List of patents

Work done	Patent no.	References
1. The procedure consists of applying many nanoparticles to a patient to locate a tumour, nanoparticles are covered with antitumor antibodies and cell-penetrating peptides (CPPs), and a polymer, as well as nanoparticles incorporating medication and/or a gene, as well as a dye or indicator in the polymer coating, at least some of the nanoparticles attaching to surface antigens of tumour cells to form a tumour cell/nanoparticle complex	US20190091350A1	US20190091350A1 (2021)
2. A peptide POD is equipped with the capacity to penetrate and supply fluorophores, siRNA, DNA, and quantum dots to cultured cells as well as in vivo retinal and eyepiece tissues. Adenovirus-decorated POD couples enhance the tropism of some cells and can provide a safer and more effective route for molecular delivery in vivo to the eye and other tissues. POD constructs are a restorative means of treatment of cells and tissues, including all ocular and retinal deterioration tissue	US8778886B2	Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits (2010)
3. The invention relates to a preparation method of a difunctional nanoparticle preparation entrapping vincristine sulphate, which belongs to the technical field of medicine. The difunctional nanoparticle preparation is prepared by entrapping the vincristine sulphate in a PLGA-PEG polymer carrier modified by folic acid/cell-penetrating peptide through a multiple emulsion method. The difunctional nanoparticle preparation shows favourable pharmacokinetic behaviour in vitro and vivo. The diameter of the prepared PLGA-PEG difunctional nanoparticles modified by folic acid/cell-penetrating peptide is 287.2 ± 0.8 nm, and the difunctional nanoparticle preparation has a high drug loading rate, high entrapment rate, and good stability	CN101926775B	CN101926775B (2021)
4. The invention relates to the modification of a cell-penetrating peptide for realizing a low-toxicity administration system with a positive targeting selecting function. The invention aims to actively convey an antitumor medicament to tumour tissues in a targeted way and make the antitumor medicament enter tumours cells to a larger extent using the administration system which can be used for activating a cell-penetrating function so that the toxicity at a nontumor position is lowered while the antitumor effect of the medicament is enhanced	CN102552929A	CN102552929A (2021)